Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Zhaoke Ophthalmology Ltd. ( (HK:6622) ).
Zhaoke Ophthalmology Ltd. has announced the enrollment of the first patient in a Phase II clinical trial for its presbyopia treatment, BRIMOCHOL PF, which aims to evaluate its efficacy and safety in Chinese patients. Additionally, the company has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO to commercialize BRIMOCHOL PF in the Middle East, and its partner Tenpoint Therapeutics has submitted a New Drug Application to the U.S. FDA for the same product. These developments signify strategic advancements in the company’s operations and potential market expansion.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Ltd. is a company focused on developing treatments for eye conditions, particularly presbyopia. The company is involved in clinical trials and partnerships to advance its pharmaceutical products in the global market.
YTD Price Performance: 21.67%
Average Trading Volume: 2,787,016
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$759.1M
Learn more about 6622 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue